New Millennium Group’s Rein Therapeutics RNTX Stock Holding History

New Millennium Group’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$2.36K	Buy	+2,038	New	+$2.81K	﹤0.01%	287

Other funds holding RNTX

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

New Millennium Group's RNTX Position: Q4 2025 in Review

New Millennium Group opened a new position in Rein Therapeutics (RNTX) in Q4 2025: 2,038 shares worth $2.36K. The stake represents ﹤0.01% of the portfolio and ranks #287 among its holdings.

48 funds tracked by Wall St. Rank hold RNTX as of Q4 2025.

New Millennium Group held 2,038 shares of Rein Therapeutics worth $2.36K as of Q4 2025.
Rein Therapeutics was a new New Millennium Group position in Q4 2025.
Rein Therapeutics made up ﹤0.01% of New Millennium Group's portfolio in Q4 2025, its #287 holding.
48 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2025.

Based on New Millennium Group's 13F filing for Q4 2025, filed 6 Feb 2026.